-

10:24:13 PM

OGEN Stock News

OGEN - Oragenics Inc

06/23/22 4:30 PM

AMEX, Nasdaq : OGEN, BWV, CRXT

management

Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck’ s HPV/Gardasil Franchise.

RHEA-AI

very positive

06/14/22 7:30 AM

AMEX : OGEN

covid-19

Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including coronavirus, announces the publication of an article co-authored by Oragenics and collaborators at Inspirevax and the National Research Council of Canada Human Health Therapeutics Research Centre in Scientific Reports, a Nature journal. These published data, and our...

RHEA-AI

neutral

05/17/22 7:30 AM

AMEX : OGEN

Oragenics Issues Letter to Shareholders

Oragenics, Inc. today issued the following letter to shareholders from its Executive Chairman, Frederick W. Telling, Ph.D.:. I thank you for your continued support of Oragenics and our vision, and am delighted to report on our recent progress. In previous letters I affirmed the strategic direction Oragenics is taking and discussed our commitment to the speedy yet...

RHEA-AI

neutral

04/18/22 7:30 AM

AMEX, Nasdaq : OGEN, BWV, CRXT

conferences

Oragenics to Participate at the World Vaccine Congress Washington 2022

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including coronavirus, today announced that Kimberly Murphy, a member of the Company’ s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’ s lead product, NT-CoV2-1, an intranasal vaccine candidate,...

RHEA-AI

neutral

04/06/22 7:30 AM

AMEX : OGEN

Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses

Oragenics, Inc. today announced it has extended a licensing and collaboration agreement with the National Research Council of Canada that enables Oragenics to pursue an intranasal vaccine designed to protect against future variants of coronaviruses. The NRC cell expression technologies provide Oragenics with a platform that can generate cell lines...

RHEA-AI

neutral

03/25/22 7:30 AM

AMEX : OGEN

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Oragenics, Inc. today announced that, as previously disclosed in its Annual Report on Form 10- K for the year ended December 31, 2021, which was filed on March 24, 2022 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an...

RHEA-AI

neutral

03/22/22 8:59 AM

AMEX : OGEN

covid-19

Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

Oragenics, Inc. today announced the initiation of a Good Laboratory Practice toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine candidate in rabbits. Oragenics has contracted with Frontage Laboratories to conduct the study, with top-line interim data expected in August. Glenn Washer, Frontage’ s North American...

RHEA-AI

neutral

03/10/22 7:30 AM

AMEX : OGEN

covid-19

Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1

Oragenics, Inc. today announced it has entered into an agreement with KBI Biopharma, Inc. for the process transfer, process optimization and cGMP manufacturing of the Company’ s intranasal vaccine candidate NT-CoV2-1, which is expressed in a proprietary CHO cell line. Successful completion of work under this agreement will enable Oragenics to secure...

RHEA-AI

very positive

03/03/22 9:09 AM

AMEX : OGEN

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

Oragenics, Inc. today announced the posting of a preprint manuscript in bioRxiv. The manuscript, co-authored by Oragenics and its collaborators at Inspirevax and the National Research Council of Canada Human Health Research Centre, is titled“ Intranasal Immunization with a Proteosome-Adjuvanted SARS-CoV2 Spike Protein-Based Vaccine is Immunogenic...

RHEA-AI

neutral

01/26/22 7:30 AM

AMEX : OGEN

Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Oragenics, Inc. announced that the Company’ s reconvened Annual Meeting of Shareholders, on January 25, 2022, at 4:00 p.m. was convened and again adjourned, without any business being conducted, due to lack of the required quorum. The Annual Meeting therefore had no quorum and the meeting was again adjourned to 4:00 p.m. on Friday, February 25, 2022 at the...

RHEA-AI

neutral

OGEN Data

Websitewww.oragenics.com
Security nameOragenics Inc
Issue typecs
Sic code2834
Employees7
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address4902 Eisenhower Blvd Ste 125
StateFlorida
CityTampa
Zip33634-6342
CountryUS
Phone18132867900

About Oragenics Inc

Oragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. The Company is dedicated to the development and commercialization of a vaccine candidate providing specific immunity from novel coronavirus. The Terra CoV-2 immunization leverages coronavirus spike protein research conducted by the National Institute of Health. In addition, Oragenics has an exclusive worldwide channel collaboration with ILH Holdings, Inc. (n/k/a Eleszto Genetika, Inc.), relating to the development of novel lantibiotics.